BGMS

#4899
Bio Green Med Solution, Inc. - Common Stock
0.8 6 USD
-0.03%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.86
0.86
Jahresspanne
0.57
6.70
Tagesänderung
-3.37%
Monatliche Änderung
-1.15%
6 month change
-10.06%
Jahresänderung
-85.67%
Vorheriger Schlusskurs
0.8 9
Open
0.8 6
Tief
0.8 6
Hoch
0.8 6
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Bio Green Med Solution, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Bio Green Med Solution, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Bio Green Med Solution, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Bio Green Med Solution, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Bio Green Med Solution, Inc. current report, Q1 FY2026
8-K

Bio Green Med Solution, Inc. current report, Q2 FY2026

Full document

Bio Green Med Solution, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed on June 10, 2026, by Bio Green Med Solution, Inc., a Delaware corporation headquartered in Kuala Lumpur, Malaysia. The report discloses the closing of a private placement transaction and the entry into material definitive agreements.

Key Financial Metrics

  • Capital Raised: $794,403 in aggregate gross proceeds.
  • Shares Issued: 1,103,338 shares of Common Stock.
  • Price Per Share: $0.72.
  • Use of Proceeds: General corporate and operating purposes.
  • Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for these metrics as this is a transaction-specific report, not a periodic financial statement.

Material Changes

The primary material change is the increase in outstanding common stock by 1,103,338 shares and the corresponding cash inflow of $794,403. The transaction closed on June 10, 2026, following a Securities Purchase Agreement dated June 10, 2025.

Outlook, Risks, and Unusual Items

  • Registration Rights: The Company entered into a Registration Rights Agreement, obligating it to file a registration statement for the resale of the shares and keep it effective until all registrable securities are sold.
  • Costs: The Company is responsible for registration expenses associated with the resale registration statement.
  • Regulatory Exemption: The shares were sold without registration under the Securities Act, relying on the exemption provided by Regulation S (sales to non-U.S. persons outside the United States).
  • Management Commentary: No specific forward-looking guidance or outlook regarding future operations was provided in this filing.

Investor Verification Checklist

  • Verify the exact number of shares outstanding post-transaction to assess dilution impact.
  • Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
  • Monitor the filing and effectiveness of the resale Registration Statement mentioned in the Registration Rights Agreement.
  • Confirm the actual utilization of the $794,403 proceeds in subsequent quarterly reports.